Clinical Trial

First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.

Study acronym: SVRI01
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of the investigational monoclonal antibody TBE025 when given intravenously to healthy adult volunteers aged 18 to 55. The study aims to determine the recommended Phase II dose of TBE025 and to assess the incidence and severity of adverse events related to its administration. There is no comparison group, as this is a single-arm, open-label study. Participants will receive a single intravenous infusion of TBE025 at one of three escalating dose levels, will be monitored for safety with regular clinical and laboratory assessments, and will provide blood samples for pharmacokinetic, anti-drug antibody, and neutralization testing.
Trial Details
NCT Number NCT07377253
Lead Sponsor Giuseppe Pantaleo
Collaborators: Rockefeller University
Conditions The Tick-borne Encephalitis Virus (TBEV)
Enrollment 18 participants
Start Date 2026-01-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-29